Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $256.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY), following report of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE